To the best of our knowledge, a histone mark-associated EED/BRD4 interaction has not been previously reported, although consistent evidence exists indicating improved tumor treatment efficacy through combined inhibitors of EZH2 and BRD4.38 This evidence concerns the gene EED and neoplasm.